giant cell arteritis
Rheumatology · 2018–2025
3decisions
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tocilizumab Tocilizumab biosimilar requested for listing under the same circumstances as the reference brand Actemra for the treatment of active giant cell arteritis,… | Nov 2025 | Recommended with restriction | none received |
| tocilizumab Treatment of patients with active giant cell arteritis (GCA) in combination with a tapering course of corticosteroids, for a maximum of 12 months. | Mar 2019 | Recommended with restriction | none received |
| tocilizumab Treatment of patients with new-onset or relapsed giant cell arteritis (GCA). | Nov 2018 | Deferred | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.